Aldeyra Therapeutics Inc

Insider buys at Aldeyra suggest potential upside, but institutional sales and bearish options warn investors to stay cautious.

Aldeira CFO’s recent 5,000‑share purchase at $1.42 signals confidence amid steep price declines, hinting insiders see value below the 52‑week low.